KIND Pharmaceuticals Excels at ASH Meeting with Promising Results for AND017 in Sickle Cell Disease and MDS KIND Pharmaceuticals presents significant findings for AND017 in hematologic diseases at the ASH 2024 meeting, announcing FDA IND approval.

KIND Pharmaceuticals Excels at ASH Meeting with Promising Results for AND017 in Sickle Cell Disease and MDS #USA #San_Diego #sickle_cell_disease #Kind_Pharmaceuticals #AND017